February 5, 2025 02:33 PM EST

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Shelby Livingston

Senior health tech reporter

Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That competition is cutting into demand for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Shelby Livingston

Senior health tech reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bristol Myers, Kyowa Kirin disclose layoffs

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

GSK defiant against vaccine challenges, will prioritize other growth areas

With first drug now in the clinic, Alys eyes megaround for rest of pipeline

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

Senior health tech reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says